SCHEMBL6074932

SCHEMBL6074932

CSc1ccc2nc(Cl)c(C=O)cc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C19 P33261 1/20 0.58
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
MPI P34949 1/20 0.47
KMT2A Q03164 1/20 0.47
GSK3B P49841 2/20 0.36
DAPK3 O43293 1/20 0.36
DYRK3 O43781 1/20 0.36
MAP4K4 O95819 1/20 0.36
CDK1 P06493 1/20 0.36
PIM1 P11309 1/20 0.36
CDK2 P24941 1/20 0.36
CSNK1A1 P48729 1/20 0.36
CLK2 P49760 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10691365 0.90 ALDH1A1 (0.65) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL1880623 0.79 ALDH1A1 (0.78) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL6304224 0.79 CYP1A2 (0.61) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL30129703 0.79 CYP1A2 (0.61) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL6304525 0.77 CYP1A2 (0.68) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL3148643 0.77 TDP1 (0.55) CYP1A2ALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL15941609 0.76 CYP1A2 (0.57) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL6905045 0.76 CYP1A2 (0.57) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL11971423 0.76 CYP1A2 (0.57) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL8672 0.76 CYP1A2 (0.57) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105537-B2 2-substituted cyclic amines as calcium sensing receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-12 US disclosed
US-20040229860-A1 Novel 2-substituted cyclic amines as calcium sensing receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004069793-A2 NOVEL 2-SUBSTITUTED CYCLIC AMINES AS CALCIUM SENSING RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-08-19 WO disclosed
US-4735948-A (1H-tetrazol-5-yl)-2(1H)-quinolinones and-naphthyridones and antiallergic use thereof MERRELL DOW PHARMACEUTICALS INC. (US) 1988-04-05 US disclosed
EP-0120484-B1 (1H-TETRAZOL-5-YL)TETRAZOLO (1,5-A)-QUINOLINES AND RELATED COMPOUNDS MERRELL DOW PHARMACEUTICALS INC. (US) 1987-04-22 EP disclosed
EP-0120483-B1 (1H-TETRAZOL-5-YL)-2(1H)-QUINOLINONES MERRELL DOW PHARMACEUTICALS INC. (US) 1987-04-01 EP disclosed
US-4496569-A Antiallergic (1H-tetrazol-5-yl)tetrazolo[1,5-a]quinolines and derivatives thereof THE DOW CHEMICAL COMPANY (US) 1985-01-29 US disclosed
EP-0120484-A1 (1H-tetrazol-5-yl)tetrazolo (1,5-a)-quinolines and related compounds MERRELL DOW PHARMACEUTICALS INC. (US) 1984-10-03 EP disclosed
EP-0120483-A1 (1H-tetrazol-5-yl)-2(1H)-quinolinones MERRELL DOW PHARMACEUTICALS INC. (US) 1984-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229860-A1 Novel 2-substituted cyclic amines as calcium sensing receptor modulators CASR, RYR1, CACNA1E CYP1A2 2760/4885CYP3A4 4124/4885CYP2D6 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.